Company research
Sight Sciences, Inc.
CIK 1531177Updated Sep 24, 2026
SecuritySGHT · NASDAQ · equity
SGHT price & chart
Loading TradingView…
NASDAQ:SGHT on TradingView ↗About the company
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System and OMNI® Edge Surgical System are implant-free, minimally invasive glaucoma surgery technologies indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The OMNI Surgical System is CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION® Surgical System is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States f…
In the news
TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease ↗
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 115,300,000Source | 142,839,000Source | 166,651,000Source | 213,073,000Source |
| Property, Plant and Equipment, NetUSD | 1,610,000Source | 1,580,000Source | 1,640,000Source | 1,571,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 91,965,000Source | 120,357,000Source | 138,129,000Source | 185,000,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 9,745,000Source | 10,786,000Source | 14,289,000Source | 15,148,000Source |
| Inventory, NetUSD | 7,767,000Source | 6,325,000Source | 7,849,000Source | 6,114,000Source |
| Assets, CurrentUSD | 112,734,000Source | 139,774,000Source | 162,871,000Source | 209,677,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,257,000Source | 2,306,000Source | 2,604,000Source | 3,415,000Source |
| Operating Lease, Right-of-Use AssetUSD | 438,000Source | 935,000Source | 1,458,000Source | 1,614,000Source |
| Other Assets, NoncurrentUSD | 518,000Source | 550,000Source | 682,000Source | 211,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 51,358,000Source | 55,316,000Source | 46,436,000Source | 52,997,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 54,000Source | 51,000Source | 49,000Source | 48,000Source |
| Retained Earnings (Accumulated Deficit)USD | -384,723,000Source | -346,297,000Source | -294,790,000Source | -239,243,000Source |
| Stockholders' Equity Attributable to ParentUSD | 63,942,000Source | 87,523,000Source | 120,215,000Source | 160,076,000Source |
| Additional Paid in Capital, Common StockUSD | 448,611,000Source | 433,769,000Source | 414,956,000Source | 399,271,000Source |
| Liabilities and EquityUSD | 115,300,000Source | 142,839,000Source | 166,651,000Source | 213,073,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 11,027,000Source | 15,468,000Source | 12,252,000Source | 17,817,000Source |
| Operating Lease, Liability, CurrentUSD | 475,000Source | 533,000Source | 573,000Source | 1,033,000Source |
| Accounts Payable, CurrentUSD | 1,343,000Source | 1,691,000Source | 1,731,000Source | 2,688,000Source |
| Operating Lease, Liability, NoncurrentUSD | 0Source | 473,000Source | 914,000Source | 635,000Source |
| Other Liabilities, NoncurrentUSD | 31,000Source | 492,000Source | 2,476,000Source | 1,867,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 2,140,000Source | 2,113,000Source | 1,639,000Source | 5,307,000Source |
| Deferred Tax Liabilities, NetUSD | 0Source | 0Source | 0Source | 0Source |
| Long-term Debt, Excluding Current Maturities | — | — | — | — |
| Long-term Debt, Current MaturitiesUSD | 0Source | 0Source | 2,219,000Source | 0Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 40,300,000Source | 39,356,000Source | 31,708,000Source | 33,313,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -38,426,000Source | -51,507,000Source | -55,547,000Source | -86,242,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 487,000Source | 712,000Source | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 13,054,000Source | 17,077,000Source | 14,581,000Source | 12,963,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -912,000Source | -3,545,000Source | -661,000Source | 6,841,000Source |
| Increase (Decrease) in InventoriesUSD | 1,442,000Source | -1,630,000Source | 2,156,000Source | 3,253,000Source |
| Increase (Decrease) in Accounts PayableUSD | -348,000Source | 336,000Source | -883,000Source | -694,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -29,694,000Source | -22,351,000Source | -47,184,000Source | -75,965,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -224,000Source | -385,000Source | -791,000Source | -970,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 224,000Source | 385,000Source | 791,000Source | 970,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 1,791,000Source | 4,964,000Source | 1,104,000Source | 1,248,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -28,127,000Source | -17,772,000Source | -46,871,000Source | -75,687,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 92,230,000Source | 120,357,000Source | 138,129,000Source | 185,000,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 4,185,000Source | 4,262,000Source | 4,267,000Source | 3,252,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 13,054,000Source | 17,077,000Source | 14,581,000Source | 12,963,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 944,000Source | 753,000Source | 614,000Source | 657,000Source |
| DepreciationUSD | 300,000Source | 500,000Source | 614,000Source | 710,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -4,000Source | -23,000Source | -66,000Source | -85,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | 0Source | -1,962,000Source | — | — |
| Income Tax Expense (Benefit)USD | 10,000Source | 236,000Source | 110,000Source | 47,000Source |
| Inventory Write-downUSD | 0Source | -106,000Source | 418,000Source | 614,000Source |
| Net Income (Loss) Attributable to ParentUSD | -38,426,000Source | -51,507,000Source | -55,547,000Source | -86,242,000Source |
| Operating ExpensesUSD | 103,765,000Source | 118,817,000Source | 126,449,000Source | 142,924,000Source |
| Operating Lease, ExpenseUSD | 585,000Source | 783,000Source | 1,157,000Source | 732,000Source |
| Other Nonoperating Income (Expense)USD | -148,000Source | -32,000Source | 7,245,000Source | 2,225,000Source |
| Proceeds from Stock Options ExercisedUSD | 1,091,000Source | 255,000Source | 395,000Source | 576,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 77,363,000Source | 79,866,000Source | 81,056,000Source | 71,331,000Source |
| Cost of RevenueUSD | 10,697,000Source | 11,581,000Source | 11,881,000Source | 12,361,000Source |
| Selling, General and Administrative ExpenseUSD | 89,159,000Source | 100,826,000Source | 108,893,000Source | 120,065,000Source |
| Operating Income (Loss)USD | -37,099,000Source | -50,532,000Source | -57,274,000Source | -83,954,000Source |
| Other Nonoperating Income (Expense)USD | -148,000Source | -32,000Source | 7,245,000Source | 2,225,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -38,416,000Source | -51,271,000Source | -55,437,000Source | -86,195,000Source |
| Income Tax Expense (Benefit)USD | 10,000Source | 236,000Source | 110,000Source | 47,000Source |
| Net Income (Loss) Attributable to ParentUSD | -38,426,000Source | -51,507,000Source | -55,547,000Source | -86,242,000Source |
| Earnings Per Share, BasicUSD per share | -0.74Source | -1.03Source | -1.14Source | -1.8Source |
| Earnings Per Share, DilutedUSD per share | -0.74Source | -1.03Source | -1.14Source | -1.8Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 52,148,543Source | 50,134,104Source | 48,628,940Source | 47,849,058Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 52,148,543Source | 50,134,104Source | 48,628,940Source | 47,849,058Source |
| Additional Financial Items | ||||
| Gross ProfitUSD | 66,666,000Source | 68,285,000Source | 69,175,000Source | 58,970,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -38,900,000Source | 51,300,000Source | 55,700,000Source | 86,000,000Source |
| Interest ExpenseUSD | 5,142,000Source | 4,662,000Source | 5,408,000Source | 4,466,000Source |
| Investment Income, NetUSD | 3,973,000Source | 5,917,000Source | — | — |
| Operating ExpensesUSD | 103,765,000Source | 118,817,000Source | 126,449,000Source | 142,924,000Source |
| Operating Lease, ExpenseUSD | 585,000Source | 783,000Source | 1,157,000Source | 732,000Source |
| Research and Development ExpenseUSD | 14,606,000Source | 17,991,000Source | 17,556,000Source | 22,859,000Source |
Filing attachments
sght-ex99_1.htm · 8-K · 2026-08-05
EX-99.1 2 sght-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Sight Sciences Reports Second Quarter 2026 Financial Results Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense Guidance MENLO PARK, Calif., August 5, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ live…
Read attachment ↗sght-ex99_2.htm · 8-K · 2026-08-05
EX-99.2 3 sght-ex99_2.htm EX-99.2 Investor Presentation August 2026 Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. The Company intends such forward-look…
Read attachment ↗sght-ex99_1.htm · 8-K · 2026-05-06
EX-99.1 2 sght-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance MENLO PARK, Calif., May 6, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the …
Read attachment ↗sght-ex99_2.htm · 8-K · 2026-05-06
EX-99.2 3 sght-ex99_2.htm EX-99.2 Investor Presentation May 2026 Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. The Company intends such forward-looking…
Read attachment ↗sght-ex99_1.htm · 8-K · 2026-03-04
EX-99.1 2 sght-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance MENLO PARK, Calif., March 4, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported fina…
Read attachment ↗sght-ex99_2.htm · 8-K · 2026-03-04
EX-99.2 3 sght-ex99_2.htm EX-99.2 Investor Presentation March 2026 Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. The Company intends such forward-looki…
Read attachment ↗